NLRP3 and non-small cell lung carcinoma: The above results indicate that downregulation of MIR503HG expression could activate the NF-κB signalling pathway and induce the expression of NLRP3 inflammasome components, which in turn promotes tumour metastasis in NETs-treated NSCLC cells.